Acclarent granted key patent covering balloon sinuplasty technologies Acclarent.
.. Acclarent granted key patent covering balloon sinuplasty technologies Acclarent, Inc. Today that the U announced.S. Patent and Trademark Office awarded U.S. Patent #7 7,500,971, entitled Devices, Systems and Options for Treating Disorders of the Hearing, Nose and Throat, to the company. This patent and Acclarent’s earlier 7,462,175 patent are directed to options for dealing with a paranasal sinus ostium, such as the maxillary sinus ostium, either through the nostril or various other routes. The patented methods consist of advancing a balloon through a guide and using the balloon to dilate a paranasal sinus ostium. Furthermore to securing protection because of this early development, we believe this key patent underscores Acclarent’s strength in intellectual house and deepens the cornerstone of our patent portfolio for Balloon Sinuplasty, states Acclarent CEO, Costs Facteau.For all sterile items from NuVision, the FDA recommends that health care providers and other healthcare professionals, including hospital staff, check their medical materials for NuVision sterile items immediately, quarantine those products, rather than administer them to individuals. Patients who had been administered any sterile medication products produced and written by NuVision and who’ve concerns should contact their health care provider.
ACM Global Central Laboratory launches enhanced version of its proprietary LabStar system ACM Global Central Laboratory, the global central lab that continually defines the customer-service standard with its flexible approach, has launched an enhanced version of its proprietary LabStarSM system, which captures all clinical trial screening data within a location for quick access and comprehensive reporting.